3 Near-Term Runners To Buy On The Current Weakness In Biotech

3 Near-Term Runners To Buy On The Current Weakness In Biotech


Management at Adamis Pharmaceuticals believes the third time is the charm for gaining approval for their cheaper alternative to the Epi-Pen. Recent recall at Mylan aids the case.



from Biotech News